Dr. Jekyll and Mr. Hyde: A short history of anthrax

Molecular Aspects of Medicine

Volumn 30, Issue 6, 2009, Pages 347-355

  Schwartz, Maxime ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Anthrax; Bacillus anthracis; Bacterial spores; Bacterial toxins; Bacterial warfare; Bioterrorism; Pathophysiology; Vaccines

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; CIPROFLOXACIN; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; BIOLOGICAL WARFARE; DRUG MEGADOSE; HUMAN; IMMUNOCOMPETENT CELL; INFECTION PREVENTION; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; REVIEW; SIGNAL TRANSDUCTION; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BIOLOGICAL WARFARE; HISTORY, ANCIENT; HUMANS;

ANIMALIA; BACILLI (CLASS); BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 70350728420     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2009.06.004     Document Type: Review

References (93)

1. Alibek K., and Handelman S. Biohazard (1999), Random House, New York
2. Bail O. Untersuchungen über natürliche und künstliche Milzbrandimmunität. Zentralbl. Bakt.Parassiten. Infektionskr. I. rig. 36 (1904) 266-272
3. Bail O., and Weil E. Beitrage zum studien der Mitzbrandinfektion. Arch. Hyg. 73 (1911) 218-264
4. Bazin H. L'histoire des Vaccinations (2008), John Libbey Eurotext, Paris
5. Beyer W., and Turnbull P.C.B. Anthrax in animals. Molecular Aspects of Medicine 30 (2009) 481-489
6. Brock T.D. Robert Koch, A Life in Medicine and Bacteriology (1988), Science Tech. Publisher, Springer Verlag, Madison
7. Clunan A.L., Lavoy P.R., and Martin S.B. Terrorism, War, or Disease? Unraveling the Use of Biological Weapons (2008), Stanford University Press, Stanford, California
8. Cohn F.J. Untersuchungen uber bakterien. Beitr. Biol. Pflanz. 2 (1876) 249-276
9. Cole, L.A., 2003. The Anthrax Letters. Joseph Henry Press, Washington, DC.
10. Cromartie W.J., Bloom W.L., and Watson D.W. Studies on infection with with Bacillus anthracis. 1. A histopathological study of skin lesions produced by B. anthracis in susceptible and resistant species. J. Infect. Dis. 80 (1947) 1-13 (See also following articles: 80, pp. 14, 28 and 121.)
11. Cybulski Jr. R.J., Sanz P., and O'Brien A.D. Anthrax vaccination strategies. Molecular Aspects of Medicine 30 (2009) 490-502
12. Dal Molin F., Tonello F., Ladant D., Zornetta I., Zamparo L., Di Benedetto G., Zaccolo M., and Montecucco C. Cell entry and cAMP imaging of anthrax edema toxin. EMBO J. 25 (2006) 5405-5413
13. Dance A. Death renews biosecurity debate. Nature 454 (2008) 672
14. Davaine C.J. Recherche sur les infusoires du sang dans la maladie connue sous le nom de sang de rate. CR. Acad. Sci. Paris 67 (1863) 220-223
15. Dirckx J.H. Virgil on anthrax. Am. J. Dermatopathol. 3 (1981) 191-195
16. Driks A. The Bacillus anthracis spore. Molecular Aspects of Medicine 30 (2009) 368-373
17. Duchesne, E., 1897. "Contribution à l'étude de la concurrence vitale chez les micro-organismes: antagonisme entre les moisissures et les microbes". Thesis, Faculté de médecine et de Pharmacie de Lyon.
18. Duclaux E. Pasteur, Histoire d'un Esprit (1896), Masson et Cie, Sceaux
19. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., and Vandewoude G.F. Proteolytic inactivation of map-kinase-kinase by anthrax lethal factor. Science 280 (1998) 734-737
20. Enserinck M., and Bhattacharjee Y. Scientists seek answers, ponder future after anthrax case suicide. Science 321 (2008) 754-755
21. Florey H.W., Chain E., Heatley N.G., Jennings M.A., Sanders A.G., Abraham E.P., and Florey M.E. Antibiotics. A Survey of Penicillin, Streptomycin, and Other Antimicrobial Substances from Fungi, Actinomycetes, Bacteria and Plants (1949), Oxford University Press, Oxford
22. Franz D.R. Preparedness for an anthrox attack. Molecular Aspects of Medicine 30 (2009) 503-510
23. Friedlander A.M., Pittman P.R., and Parker G.W. Anthrax vaccine. Evidence for safety and efficacy against inhalational anthrax. J. Am. Med. Assoc. 282 (1999) 2104-2106
24. Geison G.L. The Private Science of Louis Pasteur (1995), Princeton University Press, Princeton, New Jersey
25. Gill D.M. The arrangement of subunits in cholera toxin. Biochemistry 15 (1976) 1242-1248
26. Gill D.M., Clements J.D., Robertson D.C., and Finkelstein R.A. Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect. Immun. 33 (1981) 677-682
27. Gladstone G.P. Immunity of anthrax: protective antigen present in cell-free culture filtrates. Brit. J. Exp. Pathol. 27 (1946) 393-410
28. Goossens P.L. Animal models of human anthrax: The Quest for the Holy Grail. Molecular Aspects of Medicine 30 (2009) 467-480
29. Green B.D., Battisti L., Koehler T.M., Thorne C.B., and Ivins B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49 (1985) 291-297
30. Guillemin, J., 1999. Anthrax: The Investigation of a Deadly Outbreak. University of California Press.
31. Guillemin J. Biological Weapons: from the Invention of State Sponsored Programs to Contemporary Bioterrorism (2005), Columbia University Press, New York
32. Guillemin J. Imperial Japan's germ warfare, the suppression of evidence at the Tokyo war crime trial, 1946-1948. In: Clunan A.L., Lavoy P.R., and Martin S.B. (Eds). Terrorism, War, or Disease? Unraveling the Use of Biological Weapons (2008), Stanford University Press, Stanford, California
33. Hambleton P., and Turnbull P.C.B. Anthrax vaccine development: a continuing story. In: Mizrahi A. (Ed). Bacterial Vaccines, Advances in Biotechnological Processes vol. 13 (1990), Alan R. Liss, New York 105-122
34. Harris-Smith P.W., Smith H., and Keppie J. Production in vitro of the toxin of Bacillus anthracis previously recognized in vivo. J. Gen. Microbiol. 19 (1958) 91-103
35. Hudson M.J., Beyer B., Böhm R., Fasanella A., Garofolo G., Golinski R., Goossens P.L., Hahn U., Hallis B., King A., Mock M., Montecucco C., Ozin A., Tonello F., and Kaufmann S.H.E. Bacillus anthracis: Balancing innocent research with dual-use potential. Int. J. Med. Microbiol. 298 (2008) 345-364
36. Hugh-Jones M.E. 1996-97 Global anthrax report. J. Appl. Microbiol. 87 (1999) 189-191
37. Hugh-Jones M., and Blackburn J. The ecology of Bacillus anthracis. Molecular Aspects of Medicine 30 (2009) 356-367
38. Inglesby T.V., O'Toole T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Friedlander A.M., Gerberding J., Hauer J., Hughes J., McDade J., Osterholm M.T., Parker G., Perl T.M., Russell P.K., Tonat K., and Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. J. Am. Med. Assoc. 287 (2002) 2236-2252
39. Jacotot H., and Virat B. La longévité des spores de B. anthracis (Premier vaccin de Pasteur). Annales, Inst. Pasteur 87 (1954) 215-217
40. Keim P., Gruendike J.M., Klevytska A.M., Schupp J.M., Challacombe T., and Okinaka R. The genome and variation of Bacillus anthracis. Molecular Aspects of Medicine 30 (2009) 397-405
41. Keppie J., Smith H., and Harris-Smith P.W. The chemical basis of the virulence of Bacillus anthracis. III. The role of terminal bacteraemia in death of guinea pigs from anthrax. Brit. J. Exp. Path. 36 (1955) 315-322
42. Keppie J., Harris-Smith P.W., and Smith H. The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action. Br. J. Exp. Pathol. 44 (1963) 446-453
43. Klemm D.K., and Klemm W.R. A history of anthrax. J. Am. Med. Vet. Assoc. 135 (1959) 458-462
44. Koch R. Beiträge zur Biologie der Pflanzen. In: Cohn F. (Ed). Zweiter Band (1876), Zweites Heft, Breslau 277-310
45. In: Koehler T.M. (Ed). Anthrax. Curr. Top. Microbiol. Immunol. vol. 271 (2002), Springer, Berlin
46. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA 79 (1982) 3162-3166
47. Leppla S.H. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv. Cyclic Nucl. Protein Phosphoryl. Res. 17 (1984) 189-198
48. Manchee R.J., Broster M.G., Melling J., Henstridge R.M., and Stagg A.J. Bacillus anthracis on Gruinard Island. Nature 294 (1981) 254-255
49. Marmier L. Sur la toxine charbonneuse. Annales Inst.Pasteur 9 (1895) 523-574
50. Meselson M. Vast biosecurity expenditures require better oversight and monitoring. Nature 457 (2009) 259-260
51. Meselson M., Guillemin J., Hugh-Jones M., Langmuir A., Popova I., Shelokov A., and Yampolskaia O. The Sverdlovsk anthrax outbreak of 1979. Science 266 (1994) 1202-1208
52. Metchnikoff E. Classics in infectious diseases. Concerning the relationship between phagocytes and anthrax bacilli. Rev. Infect. Dis. 6 (1984) 761-770
53. M'Fadyean J. The colour-reaction of anthrax blood with methylene-blue: a question of priority of publication. J. Comp. Path. Therap. 17 (1904) 58-60
54. Mikesell P., Ivins B.E., Ristroph J.D., and Dreier T.M. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39 (1983) 371-376
55. Miller J., Engelberg S., and Broad W. Germs: Biological Weapons and America's Secret War (2001), Simon and Schuster, New York
56. Moayeri M., and Leppla S.H. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Molecular Aspects of Medicine 30 (2009) 439-455
57. Mock M., and Fouet A. Anthrax. Annu. Rev. Microbiol. 55 (2001) 647-671
58. Nocard M. Communication relative à l'étiologie du charbon. Bull. Soc. Centr. Med. Vet. 3 (1881) 353-355
59. Pasteur, L., 1863. In: Pasteur Vallery-Radot (Ed.) (1928), Œuvres de Pasteur, vol. 5. Masson et Cie, Paris, pp. 238-240.
60. Pasteur, L., 1870. Etudes sur la Maladie Des vers à soie, vol. 1. Gauthiers-Villars, Paris, pp. 248-257.
61. Pasteur L. Sur l'étiologie des affections charbonneuses. CR. Acad. Sci. Paris 90 (1880) 455-457
62. Pasteur L., and Joubert J. Etude sur la maladie charbonneuse. CR. Acad. Sci. Paris 84 (1877) 900-906
63. Pasteur L., and Joubert J. Charbon et septicémie. CR. Acad. Sci. Paris 85 (1877) 101-105
64. Pasteur L., Joubert J., and Chamberland C. Sur le charbon des poules. CR. Acad. Sci. Paris 87 (1878) 47-48
65. Pasteur L., Chamberland C., and Roux E. Le vaccin du charbon. CR. Acad. Sci. Paris 92 (1881) 666-668
66. Pasteur L., Chamberland C., and Roux E. Compte Rendu sommaire des experiences faites à Pouilly-le-Fort, près de Melun, sur la vaccination charbonneuse. CR. Acad. Sci. Paris 92 (1881) 1393-1398
67. Preisz H. Experimentelle Studien über Virulenz, Empfänglichkeit und Immunität beim Milzbrand. Zeitschr. Immunität.-Forsch. 5 (1909) 341-452
68. Raffel, S., 1961. Immunity. Appleton-Century-Crofts, New York, pp. 382-388.
69. Roux E., and Yersin A. Contribution à l'étude de la diphthérie. Ann. Inst. Pasteur 2 (1888) 629-661
70. Roux E., Martin L., and Chaillou A. Trois cents cas de diphtérie traités par le sérum antidiphtérique. Ann. Inst. Pasteur 8 (1894) 640-661
71. Sen S.K., and Minett F.C. Experiments on the transmission of anthrax through flies. Ind. J. Vet. Sci. 14 (1944) 149-158
72. Shlyakhov E.N., and Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine 12 (1994) 727-730
73. Singh Y., Klimpel K.R., Quinn C.P., Chaudhary V.K., and Leppla S.H. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266 (1991) 15493-15497
74. Smith H. The use of bacteria grown in vivo for studies on the basis of their pathogenicity. Ann. Rev. Microbiol. 12 (1958) 77-102
75. Smith H., Keppie J., and Stanley J.L. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. anthracis in vivo. Brit. J. Exp. Path. 36 (1955) 460-472
76. Stanley J.L., and Smith H. The three factors of anthrax toxin: their immunogenicity and lack of demonstrable enzymic activity. J. Gen. Microbiol. 31 (1963) 329-337
77. Stephen J. Anthrax toxin. Pharmac. Ther. 12 (1981) 501-513
78. Sterne M. The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis onderstepoort. J. Vet. Sci. Animal Indust. 13 (1939) 307-312
79. Tigertt W.D. Anthrax. William Smith Greenfield, M.D., F.R.C.P., Professor Superintendent, The Brown Animal Sanatory Institution (1878-1881). Concerning the priority due to him for the production of the first vaccine against anthrax. J. Hyg. Camb. 85 (1980) 415-419
80. Todd J.H. Adaptation to environment-the Pasteur anthrax vaccine in Australia. Austr. Vet. J. 69 (1992) 318-321
81. Tournier J.-N., Paccani S.R., Quesnel Hellmann A., and Baldari C.T. Anthrax toxins: A weapon to systematically dismantle the host immune defenses. Molecular Aspects of Medicine 30 (2009) 456-466
82. Toussaint H. De l'immunité pour le charbon, acquise à la suite d'inoculations préventives. CR. Acad.Sci. Paris 91 (1880) 135-137
83. Tuffier T. Ce que l'Amérique doit à Pasteur (1930), Imprimerie A, Maretheux et Pactat. Paris
84. Turnbull P. Anthrax. In: Smith G.R., and Eason C.R. (Eds). Bacterial Diseases. Topley and Wilson's Principles of Bacteriology, Virology and Immunity, vol. 3 (1990), Arnold, London 365-379
85. Turnbull P.C.B. Anthrax vaccines: past, present and future. Vaccine 9 (1991) 533-539
86. Turnbull P.C.B. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr. Opin. Infect. Dis. 13 (2000) 113-120
87. Uchida I., Sekizaki T., Hashimoto K., and Tirakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton Plasmid. J. Gen. Microbiol. 131 (1985) 363-367
88. Vitale G., Pellizzari R., Recchi C., Napolitani G., Mock M., and Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces Tyrosine/Threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248 (1998) 706-711
89. Vitale G., Bernardi L., Napolitani G., Mock M., and Montecucco C. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352 (2000) 739-745
90. Von Behring E., and Kitasato S. Ueber das Zustandekommen der diphterie-immunität bei thieren. Dtsch. Med. Wochenstr. 16 (1890) 1113-1114
91. Wilson G.S., and Miles A. Topley and Wison's Principles in Bacteriology, Virology and Immunity (1975), The Williams and Wilkins Co., Baltimore pp. 2208-2224
92. Wistreich G.A., and Lehman M.D. Microbiology and Human Disease (1973), Glencoe Press, New York pp. 493-497
93. Wolff J., Cook G.H., Goldhammer A.R., and Berkowitz S.A. Calmodulin activates prokaryotic adenylate cyclase. Proc. Natl. Acad. Sci. USA 77 (1980) 3841-3844